Dear Dr. Thomas:

Please refer to your supplemental new drug applications dated October 18, 2013, received October 18, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Afinitor® (everolimus) Tablets, 2.5 mg, 5 mg, 7.5 mg, and 10 mg, and Afinitor® Disperz (everolimus) Tablets for Oral Suspension, 2 mg, 3 mg, and 5 mg.

We acknowledge receipt of your amendments dated February 13, 2014; March 4, 2014; April 15, 2014; April 23, 2014; May 9, 2014; and June 9, 2014.

These “Prior Approval” supplemental new drug applications provide for the following:

1. Revision to Section 5.1, 5.2, to include information on opportunistic infection such as pneumocystis jiroveci pneumonia (PJP) as requested on April 9 and 15, 2014.

2. Revision to Section 6.6 Adverse Reactions, Postmarketing Experience, to add the following events: cholecystitis, cholelithiasis, arterial thrombotic events and reflex sympathetic dystrophy as requested in our Supplement Request letter dated September 30, 2013.

3. Corresponding revisions have been made to HIGHLIGHTS OF PRESCRIBING INFORMATION. Minor formatting revisions have also been made throughout the labeling.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
**WAIVER OF HIGHLIGHTS SECTION**

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion (OPDP)  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

Reference ID: 3534929
You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Frank Cross, Jr., Senior Regulatory Health Project Manager, at (301) 796-0876.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D.                         Patricia Keegan, M.D.
Acting Director                           Director
Division of Oncology Products 1          Division of Oncology Products 2
Office of Hematology and Oncology Products Office of Hematology and Oncology Products
Center for Drug Evaluation and Research  Center for Drug Evaluation and Research

ENCLOSURE:
   Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AMNA IBRAHIM
07/01/2014

JOSEPH E GOOTENBERG on behalf of PATRICIA KEEGAN
07/01/2014

Reference ID: 3534929